Biogen Idec and Eisai form new manufacturing alliance

Biogen Idec is to lease a portion of Eisai's RTP facility, where it will manufacture oral solid dose products.

Biogen Idec has announced a manufacturing alliance with Eisai Inc, based at the Research Triangle Park (RTP) in the US.

Both companies already have facilities at the park, and Biogen Idec will now lease a portion of Eisai's facility to manufacture oral solid dose products for both companies.

Eisai will provide vial-filling services for biologic therapies and packaging services for oral solid dose products, with Biogen Idec having the option to purchase the Eisai oral solid dose facility under the ten-year lease agreement.

John Cox, executive vice-president of pharmaceutical operations and technology at Biogen Idec, commented: "This innovative capacity-sharing relationship with Eisai fits strategically in our global drug supply network, particularly as we advance our oral therapeutics."

Lou Arp, general manager of Eisai's RTP site and president of global oncology manufacturing, said that he looks forward to collaborating with Biogen Idec.

He claimed that the alliance will enable both companies to focus on their respective areas of expertise, while continuing to deliver "high-quality and innovative products".

"Moreover, employees will benefit by working in a highly collaborative environment that offers opportunities to further cultivate their careers," he added.

As part of the agreement, approximately 50 of Eisai's employees will join Biogen Idec's workforce, which already numbers 1,000-plus.